Lanean...
ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS
Atypical Teratoid/Rhabdoid tumor (AT/RT), characterized by loss-of-function mutations in the SMARCB1 component of the SWI/SNF chromatin-remodeling complex, remains a difficult-to-treat tumor with a five-year overall survival rate of 15–45%. Proteasome inhibition (PI) has recently been opened as an a...
Gorde:
| Argitaratua izan da: | Neuro Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6011927/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.016 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|